Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
about
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allPharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsEfavirenz in the therapy of HIV infection.CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in IndiaIsoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionInitiating antiretrovirals during tuberculosis treatment: a drug safety review.Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersThe Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionCYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settingsDose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIVRise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South IndiaPharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.Efavirenz: a decade of clinical experience in the treatment of HIV.Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisEvaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without TuberculosisLong-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
P2860
Q24606937-3344874E-903F-42E7-9A8E-E7534DF69B1AQ24609011-213AC220-558E-4ED2-BEC1-E283F5CF98B4Q24631021-BD78DAB1-C335-4787-931A-EB2A453C1639Q33607011-05DF067A-CD18-4D1D-B412-727D449B3128Q33623024-7A7EB6AC-5BED-4874-85D3-8887B38E3A92Q33785839-1BA1630E-0D5C-4968-91C2-293C249F5815Q33798516-C40228CA-1F5B-4FC3-AC51-8502B248E48DQ34976284-60ED0E15-4CB1-4D00-B22A-5E1C2644F730Q35043048-D5110382-BA9A-4AF2-9638-DA92A003F809Q35065867-F23521E6-4A8A-47DB-A238-170AA9FDE8CBQ35111300-3F6A8726-76C9-47CE-80CE-6B779F814BD8Q35518558-5241900A-4639-4A03-B68E-ED1981C0EDE6Q36031230-D16321CC-BC2D-42FF-8131-F006A532C061Q36840809-F6649941-05F3-41F1-AB8A-6A1B033FC4EEQ37015588-EAB93592-D0EC-43F7-A365-69CC79BD70B4Q37115738-E1FF633B-1348-4ED9-B9EF-A8D789488327Q37186259-8CC2766D-21B9-4B8A-9027-5FB8CDE50EBBQ37383949-99C02E34-EFFD-47C3-9B36-50BEAA0360A2Q37392789-918A4E9C-B89E-4C89-99AC-E14BC857D808Q37466856-5CC7E2FF-67A8-4AF5-9CED-7BE21EFA962CQ38103370-EECAAA7C-5AAE-4F38-AB1C-5AA7E5AA9CD6Q38175870-DAE7082E-4040-4CA4-83EF-FC8414E3EC2CQ38207924-692DF5DB-0437-4C3D-8BA4-2FAC38045673Q39773047-D6813875-2F76-47E9-9C02-6DDC7A6E02DCQ40694902-3395DAD5-274C-4BD4-BA4F-6558A65E8D44Q46118142-8DA1B621-602E-4045-8F6F-B32D93D98802Q56829837-5F76C180-EA1A-4D06-9077-5D2D6261B247Q58612379-9D213125-9DA6-4E0A-8C0C-0370FB2307F9
P2860
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@en
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@nl
type
label
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@en
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@nl
prefLabel
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@en
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@nl
P2093
P1433
P1476
Multiple-dose pharmacokinetics ...... icin in HIV-positive patients.
@en
P2093
Anna Cristina C Carvalho
Giampiero Carosi
Giuseppina De Iaco
Lina Tomasoni
Maria Cusato
Maria Manfrin
Mario Regazzi
Paola Villani
Silvio Caligaris
Susanna Capone
P304
P356
10.2174/157016207780636588
P577
2007-05-01T00:00:00Z